top of page

ImmunoMet Therapeutics Receives IND Clearance and Orphan Drug Designation from U.S. FDA for IM156 in Ideopathic Pulmonary Fibrosis and Completes Financing

Feb 08, 2021

HOUSTON--(BUSINESS WIRE)--ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-fibrotic and anti-cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for IM156, an investigational Protein Complex 1 inhibitor, being evaluated for idiopathic pulmonary fibrosis (IPF) as well as granting it Orphan Drug Designation.


The Art of Capturing Beauty at the Nanoscale

bottom of page